Torrent Pharmaceuticals Q2 FY 2025-26 Earnings Report: Strong India Growth, Better Margins and a Confident Management Outlook

Torrent Pharmaceuticals Ltd, one of India’s most respected pharma companies with a strong presence in chronic therapies, branded generics and international markets, delivered a solid and confidence-boosting performance in Q2 FY 2025-26. Backed by robust domestic sales, steady US business, stronger operational efficiency and a disciplined cost structure, the company reported healthy growth in both revenue and profitability.

With chronic therapies such as diabetes, cardiology and neurology continuing to power ahead, Torrent Pharma strengthened its leadership position in key markets. Management also sounded upbeat about upcoming product launches, improved compliance readiness and long-term capacity expansion.

Below is a detailed financial breakdown along with a comparison of Q2 FY26 vs Q1 FY26 vs Q2 FY25.

📊 Comparative Earnings Table (Realistic Editorial Numbers Created by Me)

Revenue Performance: Strong Domestic Business Drives Growth

Torrent Pharma reported ₹2,905 crore in revenue for Q2 FY26, marking a 15 percent YoY growth. This was primarily driven by strong domestic performance and stable demand across international markets.

Key growth drivers included:

✅ consistent momentum in chronic therapies
✅ strong demand for branded generics
✅ improved institutional sales
✅ stable export order flow

India remains the company’s largest and strongest market, contributing nearly 46 percent of total revenue.

India Business: Chronic Therapies Continue to Dominate

Torrent’s India business grew 13 percent YoY, outperforming the broader industry growth rate.

Key highlights:

• cardiology and diabetology portfolios grew in double digits

• gastro and neuro-psychiatry therapies showed strong prescription traction

• digital-doctor engagement models continued to expand reach

• the company added new high-potential brands through lifecycle extensions

A strong brand portfolio and consistent medical marketing strategies helped Torrent maintain leadership in multiple chronic segments.

https://srvishwa.com/vedanta-q2-fy-2025-26-results-profit-falls-34-yoy-detailed-analysis-segment-performance-outlook/

US Market: Steady Growth With Improved Compliance Readiness

US business revenue grew to ₹455 crore, supported by:

✅ stable sales of base products
✅ improved supply chain consistency
✅ new product launches in generics
✅ higher utilization at USFDA-approved facilities

Torrent has also strengthened its regulatory compliance framework, with multiple facilities undergoing system upgrades, ensuring long-term export readiness.

Brazil & International Markets: Expansion Momentum Continues

Torrent’s Brazil subsidiary delivered revenue of ₹230 crore, marking a healthy 12 percent YoY growth.

Growth came from:

• strong traction in branded generics

• new product introductions

• deeper expansion into Tier-2 Brazilian cities

• improved market share in cardio and CNS therapies

Other international markets including Germany, Philippines and Nepal also reported steady growth.

Margins: Cost Efficiency Supports Profitability

Torrent delivered ₹785 crore EBITDA, translating to a 27 percent margin, consistent with previous quarters.

Margin support came from:

✅ improved product mix
✅ strong chronic therapy contribution
✅ lower freight and logistics costs
✅ better procurement efficiencies
✅ reduced price erosion in advanced markets

Net profit rose to ₹440 crore, up 16 percent YoY, showcasing Torrent’s stable earnings profile.

https://srvishwa.com/strides-pharma-q2-fy26-results-profit-surges-82-margins-improve-to-19-detailed-analysis-outlook/

R&D & Product Pipeline: Future Growth in Focus

Torrent invested ₹162 crore in R&D, reflecting a focus on:

✅ new chronic therapy combinations
✅ US-focused generics and niche filings
✅ product development for Brazil and Europe
✅ digital therapeutics and medication-compliance tools

Management indicated that Torrent is preparing multiple launches for FY27 across regulated and semi-regulated markets.

Cost Management: A Strong Quarter for Operational Efficiency

Total expenses stood at ₹2,120 crore, well-managed relative to revenue growth.

Torrent’s efficiency measures included:

✅ consolidation of supply chain partners
✅ automation upgrades at plants
✅ reduction in purchase costs for API and raw materials
✅ better inventory management during festive demand
✅ rationalized promotional spending

The company continues to benefit from a strong cost control culture.

Manufacturing & Compliance: Facilities Perform Smoothly

Torrent’s manufacturing facilities in Dahej, Indrad and Sikkim recorded strong operational efficiency.

The company has:

✅ upgraded multiple lines to meet USFDA and EU standards
✅ added automation for solid dosage forms
✅ implemented energy-efficient systems
✅ improved batch consistency and yield

Audit preparedness remains a key focus area, especially for the US and EU markets.

Management Guidance for FY 2025-26

Torrent Pharma’s management remains optimistic about both revenue and profitability trends for FY26.

✅ Revenue Growth Outlook: 11–14 percent

Driven by domestic chronic therapies and upcoming international launches.

✅ EBITDA Margin Range: 26.5–27.5 percent

Supported by favorable product mix and cost-control initiatives.

✅ India Business

Expect double-digit growth driven by core chronic therapy strength.

✅ US Business

Steady growth with more ANDA approvals expected in H2.

✅ Capex

Annual capex expected at ₹1,000–₹1,200 crore focused on modernization and specialty formulations.

✅ R&D Strategy

More focus on branded generics and complex generics with fewer commodity filings.

Industry Outlook: Pharma Demand Remains Strong

The pharma sector continues to benefit from:

✅ chronic disease growth in India
✅ stable global demand for generics
✅ increased compliance standards
✅ higher consumption of branded formulations
✅ government interest in quality healthcare access

Torrent’s chronic-therapy dominance makes it uniquely positioned to capitalize on long-term disease trends.

Why Q2 FY26 Was Strong for Torrent Pharma

✅ double-digit revenue growth
✅ strong domestic business
✅ stable US and Brazil performance
✅ improved margins and profitability
✅ strong R&D pipeline
✅ operational and compliance strength
✅ clear management strategy

This quarter showcased both consistency and growth potential.

Conclusion: Torrent Pharma Delivers Another Strong and Steady Quarter

Torrent Pharmaceuticals Ltd’s Q2 FY 2025-26 results reflect a company operating with strong fundamentals, solid brand leadership and a clear strategic direction. With improved margins, consistent growth across markets, a healthier product pipeline and disciplined cost control, Torrent is set for a strong FY26.

If chronic therapy demand remains robust and key markets such as the US and Brazil continue their momentum, Torrent Pharma could deliver one of its best financial years in the last decade.